Literature DB >> 9259327

Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.

G Lazennec1, T R Ediger, L N Petz, A M Nardulli, B S Katzenellenbogen.   

Abstract

The estrogen receptor (ER) belongs to a large family of nuclear receptors, many of whose members function as ligand-dependent transcriptional activators. The mechanism by which the receptor is converted from an inactive into an activated state is not yet completely understood. To investigate the kind of changes in receptor conformation and interactions that are involved in this activation, we have used the wild type ER and a set of constitutively active ER point mutants that show from 20% to nearly 100% activity in the absence of estrogen. These mutants are of particular interest as they could mimic, in the absence of ligand, the activated state of the wild type receptor. We have analyzed several transcriptional steps that could be involved in the activation: the ability of these receptors 1) to interact with several coactivators (steroid receptor coactivator-1, SRC-1; transcription intermediary factor-1, TIF-1; and estrogen receptor-associated protein 140, ERAP 140) and with members of the preinitiation complex [TATA box-binding protein (TBP), transcription factor IIB (TFIIB)]; 2) to exhibit conformational changes revealed by proteolytic digest patterns similar to those observed for the wild type hormone-occupied ER; and 3) to bend estrogen response element-containing DNA, which is thought to be one of the important phenomena triggering transcriptional activation. Our results demonstrate that the interaction of these mutant receptors with coactivators is likely to be one of the features of the activated step, as the mutant receptors interacted with some coactivators in a ligand-independent manner in proportion to their extent of constitutive activity. However, the different degrees of ligand-independent interaction of the mutant ERs with the three coactivators suggest that SRC-1, TIF-1, and ERAP 140 may play different roles in receptor activity. Limited proteolytic digest experiments reveal that the activated state of the receptor corresponds to a particular conformation of the receptor, which is fully observed with the mutant ER showing the highest activity in the absence of estrogen. Finally, it appears that in inactive or active states, the receptor exhibits distinctly different DNA-bending abilities. Addition of estradiol is able to modify the bending ability of only the wild type receptor, whereas estradiol has no influence on the constitutive receptors, which exhibited the same bending ability as that observed for the ligand-occupied wild type receptor. These data document that the ER undergoes major changes in its conformation and also in its functional properties when it is turned from an inactive into an active state and that mutational changes in the ER protein that result in constitutive, hormone-independent activation mimic many of the changes in ER properties that are normally under hormone regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259327     DOI: 10.1210/mend.11.9.9983

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  28 in total

1.  Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1.

Authors:  F M Sladek; M D Ruse; L Nepomuceno; S M Huang; M R Stallcup
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity.

Authors:  P G Martini; R Delage-Mourroux; D M Kraichely; B S Katzenellenbogen
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

4.  NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses.

Authors:  Kendall W Nettles; John B Bruning; German Gil; Jason Nowak; Sanjay K Sharma; Johnnie B Hahm; Kristen Kulp; Richard B Hochberg; Haibing Zhou; John A Katzenellenbogen; Benita S Katzenellenbogen; Younchang Kim; Andrzej Joachmiak; Geoffrey L Greene
Journal:  Nat Chem Biol       Date:  2008-03-16       Impact factor: 15.040

5.  Interaction of Estrogen Receptor Associated Protein (ERAP) 140 with ER beta decreases but its expression increases in aging mouse cerebral cortex.

Authors:  Vijay Paramanik; M K Thakur
Journal:  Cell Mol Neurobiol       Date:  2010-05-06       Impact factor: 5.046

6.  A polymorphism in the nuclear receptor coactivator 7 gene and breast cancer susceptibility.

Authors:  Julia Süllner; Claus Lattrich; Julia Häring; Regina Görse; Olaf Ortmann; Oliver Treeck
Journal:  Oncol Lett       Date:  2011-09-16       Impact factor: 2.967

7.  Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells.

Authors:  S Misiti; S Nanni; G Fontemaggi; Y S Cong; J Wen; H W Hirte; G Piaggio; A Sacchi; A Pontecorvi; S Bacchetti; A Farsetti
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

8.  Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.

Authors:  Mary J Laws; Yvonne Ziegler; Sayyed Hamed Shahoei; Parama Dey; Sung Hoon Kim; Mayuri Yasuda; Ben Ho Park; Kendall W Nettles; John A Katzenellenbogen; Erik R Nelson; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2020-04-10       Impact factor: 4.872

Review 9.  Inside the supergene of the bird with four sexes.

Authors:  Donna L Maney; Jennifer R Merritt; Mackenzie R Prichard; Brent M Horton; Soojin V Yi
Journal:  Horm Behav       Date:  2020-09-19       Impact factor: 3.587

10.  Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Authors:  Yuechao Zhao; Mary J Laws; Valeria Sanabria Guillen; Yvonne Ziegler; Jian Min; Abhishek Sharma; Sung Hoon Kim; David Chu; Ben Ho Park; Steffi Oesterreich; Chengjian Mao; David J Shapiro; Kendall W Nettles; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.